Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)

#1014

Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.

Aim(s): To investigate the prevalence of hypocalcemia during treatment.

Materials and methods: Three out of 12 patients with pNETs treated with sunitinib developed grade 1, 2 and 4 hypocalcemia.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Alexandraki K, Karnezis J, Kaltsatou M, Chatzelis E, Tsoli M,

Keywords: Sunitinib, pNET, hypocalcemia,

To read the full abstract, please log into your ENETS Member account.